PXVX-0317 is a Subunit Vaccine owned by Emergent BioSolutions, and is involved in 9 clinical trials, of which 6 were completed, 2 are ongoing, and 1 is planned.

PXVX-0317 works by stimulating the immune system to produce antibodies against E1 and E2 antigens. When the body is exposed to foreign organisms, it triggers the activation of immune system via pathogen associated signals. The immune system releases antibodies to blunt the infection.

The revenue for PXVX-0317 is expected to reach a total of $151m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the PXVX-0317 NPV Report.

PXVX-0317 was originated by National Institute of Allergy and Infectious Diseases and is currently owned by Emergent BioSolutions.

PXVX-0317 Overview

PXVX-0317 is under development for the prevention of chikungunya viral infection. The therapeutic candidate is administered through intramuscular route. The vaccine candidate is a virus like particle vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins.

Emergent BioSolutions Overview

Emergent BioSolutions (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises, and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent’s pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.

The company reported revenues of (US Dollars) US$1,792.7 million for the fiscal year ended December 2021 (FY2021), an increase of 15.3% over FY2020. In FY2021, the company’s operating margin was 19.7%, compared to an operating margin of 27.9% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 19.6% in FY2020. The company reported revenues of US$240 million for the third quarter ended September 2022, a decrease of 1.1% over the previous quarter.

Quick View – PXVX-0317

Report Segments
  • Innovator
Drug Name
  • PXVX-0317
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.